Psoriasis is a chronic, immune-mediated, inflammatory skin disease, affecting 1-3% of the white population. Although the existence of two psoriasis incidence peaks has been suggested (one in adolescence before 20 years of age and another in adulthood), its onset may occur at any age, including childhood and adolescence, in which the incidence is now estimated at 40.8 per 100,000. As for adult psoriasis, pediatric psoriasis has recently been associated with obesity, metabolic syndrome, increased waist circumference percentiles and metabolic laboratory abnormalities, warranting early monitoring and lifestyle modifications. In addition, due to psoriasis' chronic nature and frequently occurring relapses, psoriatic patients tend to have an impaired quality of life, often requiring long-term treatment. Therefore, education of both pediatric patients and their parents is essential to successful and safe disease management. Given the lack of officially approved therapies, the very limited evidence-based data from randomized controlled trials, and the absence of standardized guidelines, to date, pediatric psoriasis treatment is primarily based on published case reports, case series, guidelines for adult psoriasis, expert opinions and experience with these drugs in other pediatric disorders coming from the disciplines of rheumatology, gastroenterology and oncology.
INTRODUCTION
Psoriasis is a chronic inflammatory skin disease that affects 1-3% of the population [1] . This multifactorial papulosquamous disorder is also believed to be common in pediatrics [2] .
Particularly, psoriasis is reported to affect 0.5-1% of children in Europe [3] . Moreover, the incidence of pediatric psoriasis is significantly increased over time, being now estimated at 40.8 per 100,000 with a median age onset between 7 and 10 years [4, 5] . Furthermore, a few prevalence surveys have demonstrated that about one-third of psoriasis patients sometimes develop their symptoms during childhood, although some of these may not be diagnosed until adulthood [6, 7] . Since children differ from adults, specific guidelines underlining clinical pictures and management are needed to support early intervention, which is also fundamental to achieving psychological comfort and preventing the appearance of comorbidities, apart from controlling and limiting the burden of the disease [8] . However, there are currently no international standardized guidelines for medical treatment of pediatric psoriasis. Indeed, to date, treatment is primarily based on published case reports, case series, guidelines for adult psoriasis, expert opinions and experience with these drugs in other pediatric disorders. As a consequence, most anti-psoriatic drugs, especially systemic ones, are often used off label [2] . This review focuses on the use of systemic treatments in pediatric psoriasis and their specific and peculiar features analyzing the few literature evidences and studies regarding systemic therapy in childhood psoriasis management.
METHODS
We searched for English-language literature regarding systemic treatments in pediatric psoriasis in the following databases through 7 This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
MANAGEMENT OF PEDIATRIC PSORIASIS: SYSTEMIC THERAPY
The management of pediatric psoriasis is a complicated and intriguing task. Standardized guidelines for the treatment of children with psoriasis are lacking, although certain published psoriasis guidelines for adults address several issues that concern younger populations [9, 10] . Both available systemic therapies for pediatric psoriasis and randomized controlled trials supporting their use are limited, so that physicians have to rely on data from case reports and case series from the field of dermatology as well as from the application of the same drugs but for rheumatologic or gastroenterological pediatric conditions. Given the lack of guidelines, a general approach should be performed (Table 1) : the choice of the most appropriate treatment should be influenced by several factors such as patient age, clinical severity of the disease, the impact on quality of life, the psychological burden of the condition, the presence of comorbidities (psoriatic arthritis, obesity, etc.), as well as the patient's previous treatments and preferences [2, 11] .
PHOTOTHERAPY
Children with psoriasis typically respond very well to treatment with phototherapy, which is considered an appropriate treatment in case of debilitating palmo-plantar psoriasis, diffuse psoriasis involving more than 15-20% of the body surface area, refractory plaque/ guttate/pustular psoriasis or patients who cannot receive systemic drugs for their moderate to severe psoriasis [12] . There are three main alternatives: broadband ultraviolet B (BB-UVB, 280-320 nm), narrowband (NB)-UVB (311-313 nm) and UVA (320-400 nm). They inhibit DNA synthesis and keratinocyte proliferation and induce apoptosis of T lymphocytes and production of anti-inflammatory mediators [13] . BB-UVB comprises the most active portion of sunlight radiation and produces excellent responses in case of guttate psoriasis. NB-UVB is less erythemogenic than BB-UVB and has been shown to be effective especially for guttate or thin plaque disease; it is now considered the first-line phototherapy, because of its association with milder side effects [14, 15] . Short-term side effects from UVB phototherapy have been well described also in pediatric population and comprise dry skin, itch, erythema, blistering and herpes virus activation [16] . On the other hand, long-term side effects, mainly consisting of premature photoaging and carcinogenesis, are not well documented in children [15, 16] . However, the cumulative effect of UVB phototherapy and chronic sun exposure has been linked to skin cancer. Thus, long-term follow-up of psoriatic children who attend [12, 26] . Indeed, PUVA is now rarely used in children because of long-term toxicity; topical PUVA treatments are generally preferred [15] .
NON-BIOLOGIC SYSTEMIC DRUGS
Severe or refractory plaque, pustular or erythrodermic psoriasis and psoriatic arthritis (PsA) require systemic drugs. As in adults, non-biologic systemic drugs used for pediatric psoriasis ( Systemic agents may be combined with use of topical agents and/or phototherapy in order to enhance efficacy and reduce the risk of adverse effects [27] . A very recent French multicenter retrospective study collecting data from 2000 to 2014 regarding 154 children with moderate to severe psoriasis showed that acitretin was the most frequently used therapy (54.4%) and was mainly used as first-line treatment (76.6%) [28] .
The authors also highlighted the favorable safety profile of systemic treatments in psoriatic children reporting side effects in only 33.7% subjects with most of them being benign and not presenting influence on treatment duration. Based on this study, acitretin, MTX and CsA may be considered as first-line therapy for childhood psoriasis with an acceptable efficacy and few adverse effects, with acitretin seeming efficient on plaque, pustular and palmoplantar psoriasis, MTX on plaque and guttate psoriasis, and CsA on erythrodermic and palmoplantar psoriasis [28] . However, the choice of agent remains a challenge because of the limited number of clinical trials and lack of guidelines in this age group. On the other hand, also other non-biologic systemic treatments for pediatric psoriasis have been described in the literature even if their use seems to be limited in selected countries (Germany and The Netherlands for fumarates and Japan for etretinate). However, most of the systemic treatments are not approved to use in children and are used off label [29] . Therefore, daily practice clinical decision making can be complicated and challenging.
Acitretin
Acitretin is a second-generation aromatic retinoid suitable for children with generalized flares and pustular psoriasis as intermittent rescue therapy and in case of pustular, erythrodermic or severe plaque psoriasis of older children as long-term therapy [30] . This drug can also be associated with topicals and NB-UVB phototherapy [18] . However, no randomized controlled trials exist for this drug in childhood psoriasis [31] . Oral retinoids are safe in children, as verified by long-term follow-up of patients with keratinization diseases, but always require monitoring [32] .
Treatment dosages should be B0.5 to 1 mg/ kg/day to limit the appearance of toxicity. Young females of childbearing potential should not use acitrenin or combine its use with oral contraceptive therapy, avoiding pregnancy for 3 years after drug withdrawal [30] . Effects on bone seem to be associated only with long-term use of high acitretin doses, whereas the link between radiologic modifications of the skeletal system and long-term use of low acitretin doses is still unclear [34, 35] . No correlation between skeletal abnormalities and dose or duration of treatment has been shown, and no evidence of a link between hyperostosis or increased risk of osteoporosis and prolonged retinoid therapy has been reported [36, 37] . Nevertheless, bone and spine radiology together with regular growth parameter assessment should be applied in children on long-term retinoid therapy [12] . Case reports and small case series showed acitretin use in childhood psoriasis either as monotherapy or in combination with corticosteroids, MTX, NB-UVB phototherapy or PUVA, especially for the treatment of pustular psoriasis and erythrodermic psoriasis. Although clinical improvement was generally reported after 2-3 months of therapy, recurrence of disease necessitating intermittent therapy appeared to be common. However, overall the use of acitretin was well tolerated, and adverse effects were minimal [18, [38] [39] [40] [41] [42] [43] [44] [45] [46] .
Methotrexate
Methotrexate is an antimetabolite that modulates the immune system and the inflammatory processes. Its anti-psoriatic use dates back to the 1950s, and its prescription for severe psoriasis is still the most frequent worldwide [47] . MTX is considered the systemic treatment of choice for children with moderate-to-severe plaque psoriasis [31] . However, its use in childhood is also appropriate for PsA, extensive, recalcitrant, severe or disabling psoriasis, and erythrodermic or generalized pustular disease resistant to topical and phototherapy [12] .
In children, MTX advantages include the efficacy and weekly oral dose (0.2-0.7 mg/kg/ week) [48] . [49] . As soon as therapeutic control has been achieved, it is recommended to taper the dose to an effective but lower maintenance dose to reduce side effects [50] .
Parenterally administered MTX is only used in case of unsuccessful oral therapy or gastrointestinal side effects [17] . This drug is associated with many potential side effects, mainly nausea, vomiting, fatigue, hematological abnormalities, hepatotoxicity, pulmonary toxicity and drug interactions, which need clinico-laboratory monitoring [51] .
Clinical experience usually reports minor short-term side effects with MTX use [31] .
However, since the total cumulative dose of MTX is linked to hepatotoxicity, it should not be used if children require many years of systemic therapy [17] . transplant patients with more than 6 months of age [12] . However, this drug is also useful in severe psoriasis, including pustular and erythrodermic variants of the disease, in case of ineffective previous treatment and in short-term crisis management [67] [68] [69] . Indeed, case series and reports support the use of CsA in the treatment of recalcitrant plaque and pustular juvenile psoriasis at doses of 1.5-5 mg/kg/day for 6 weeks-2 years [67] [68] [69] [70] [71] .
CsA effects can be clinically observed in 4-8 weeks so that it is considered the ideal drug for the control of unstable disease because of its rapid onset of action [11] . With the aim of increasing efficacy and decreasing toxicity, the drug can be associated with topical and other systemic treatments [72] . The CsA dose, which usually ranges from 3 to 5.0 mg/kg/day, influences the rate of improvement and should be progressively tapered to the lowest one needed to control disease [69] . CsA may present pharmacokinetic differences between children and adults: in children oral absorption may be lower, clearance is more rapid, and volume distribution at a steady state is greater [71] . Therefore, cases of childhood psoriasis may require higher dosages of CsA, or doses should be administered three times per day [71] . In general, treatment duration should not exceed 12 months, and close monitoring of renal function is mandatory. Indeed, the risk of renal toxicity, hypertension and immunosuppression limits CsA use; thus, laboratory and blood pressure monitoring before and during treatment is essential [73] .
Other adverse events include nausea, diarrhea, myalgias, headache, electrolyte abnormalities (hyperkalemia and hypomagnesemia), hyperlipidemia, hypertrichosis and gingival hyperplasia. A matter of concern, also in children, is the risk of malignancies, in particular skin cancer and lymphoproliferative diseases; however, this risk seems to be negligible using doses B5 mg/kg/day and avoiding the association of CsA with other immunosuppressive treatments [74] . Indeed, although CsA can be combined with several topical or systemic agents (acitretin), in order to reduce the total dose and duration of the two combined agents [19] , the association with NB-UVB is usually avoided because of the potential long-term risk of developing nonmelanoma skin cancer [52] [79] . Therefore, the choice of using etretinate rather than acitretin is uncommon and usually characterizes Asian countries (Japan above all)
where acitretin use is not approved or reimbursable by health insurances [80] .
Etretinate use is described in about 14 pediatric patients with pustular psoriasis. Dosage ranged from 0.25 to 1.5 mg/kg/day, showing remarkable or excellent improvement in most cases [43, [80] [81] [82] [83] [84] . Side effects included xerosis, skin fragility and transient elevations of liver enzymes, lactic dehydrogenase, and cholesterol and triglyceride levels. Apart from teratogenicity, for which reason it should be not used in young females of childbearing potential, the major problem in treating children with etretinate is the risk of skeletal toxicity; therefore, radiographs of the spine and bone age should be periodically monitored as in the case of acitretin, given their similarities [85] .
Fumaric Acid Esters
Fumaric acid esters (FAEs) are small molecules with a broad range of immunomodulatory effects [86] . FAE use was recently described in 14 pediatric patients with plaque psoriasis. German countries where it is usually used [90] .
Indeed, FAEs are a recommended first-line therapy in the German S3 guideline for the treatment of adult psoriasis, but its use still remains an off-label treatment in this age group [91] . pathway inhibitor (ustekinumab) for the treatment of severe and/or recalcitrant psoriasis and PsA in adults [92] . Nevertheless, evidence supporting the role of biologic agents in the treatment of pediatric psoriasis is lacking.
BIOLOGIC DRUGS
Indeed, the exact role of biologics in the treatment of pediatric psoriasis remains undefined but is evolving. Biologics are an attractive option for use in children in part because they offer more convenient dosing regimens and less frequent laboratory monitoring than other systemic agents. Future research is needed to determine the efficacy, pediatric dosing and long-term safety of these agents (Table 3) .
Etanercept
Etanercept has the majority of literature papers recommending its use for childhood psoriasis [93] [94] [95] . It is a soluble tumor necrosis factor receptor fusion protein that reversibly binds to tumor necrosis factor, administered twice weekly by subcutaneous injection. In children, it has been FDA approved only for the treatment of juvenile idiopathic arthritis (JIA) [96] , although, in 2009, the European Commission approved it for the treatment of children C6 years old with chronic severe plaque psoriasis intolerant or resistant to non-biologic systemic therapies, also including phototherapy [97] . The best data for its efficacy and safety in pediatric psoriasis come from a randomized, double-blind phase III clinical trial in which 211 pediatric patients aged 4-16 years with moderate to severe plaque psoriasis were treated with etanercept (0.8 mg/kg/week) over 48 weeks. No opportunistic infections (including tuberculosis), demyelinating diseases, tumors or deaths were found [94] .
Moreover, an open-label extension period of this study confirmed its efficacy and safety by evaluating 69 patients who remained in the study for up to 264 weeks, achieving the clear/ almost clear status [98] . Upper respiratory tract infections, pharyngitis, injection site reactions 
CONCLUSION
Psoriasis is a chronic inflammatory skin disease, which is quite common in children. It begins in childhood in almost one-third of the cases, and it is increasing in prevalence and incidence. Therefore, clinicians must maintain a clinical suspicion for the diagnosis of psoriasis at all ages. Even if both topical and systemic therapies are available, pediatric psoriasis treatment may often be challenging mainly because of the absence of standardized guidelines and the very limited evidence-based data from randomized controlled trials. Particularly, the evidence on systemic treatment efficacy and safety is still limited, and long-term data in pediatric patients are lacking so that physicians usually have to rely on published experience from case reports and case series also from other pediatric conditions coming from the disciplines of rheumatology, gastroenterology and oncology. Hence, in everyday practice, clinicians must follow a general approach maximizing the benefit-risk ratio ( 
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